SOPHIRIS BIO
Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is currently in Phase 3 clinical development with a blinded interim analysis expected in the second half of 2014 followed by a complete data analysis in the second half of 2015. For more information, please visit www.sophiris.com.
SOPHIRIS BIO
Industry:
Biopharma Biotechnology Clinical Trials
Founded:
2002-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.sophiris.com
Total Employee:
1+
Status:
Closed
Contact:
858.777.1760
Email Addresses:
[email protected]
Total Funding:
47.23 M USD
Technology used in webpage:
Font Awesome Apache IPv6 Facebook Sharer Microsoft IIS 8 Network Solutions DNS Citrix NetScaler Time Warner Confluence Networks
Similar Organizations
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Sophiris Bio
Aspire Capital Partners LLC
Aspire Capital Partners LLC investment in Post-IPO Equity - Sophiris Bio
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Sophiris Bio
Warburg Pincus
Warburg Pincus investment in Venture Round - Sophiris Bio
Official Site Inspections
http://www.sophiris.com
- Host name: 208.91.197.27
- IP address: 208.91.197.27
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
